The Theranostics Market Products landscape comprises three highly interconnected component categories essential for the closed-loop treatment model.

1. Radiopharmaceuticals (Agents): This segment includes therapeutic isotopes (like Lutetium-177 and Radium-223) and diagnostic imaging agents (like Gallium-68 and Fluorine-18).

2. Diagnostic Imaging Equipment: High-end systems critical for visualizing the target, such as PET/CT and SPECT/CT scanners, which provide molecular and anatomical information, respectively.

3. Companion Diagnostics (CDx): In-vitro diagnostic tests, primarily molecular assays (PCR or NGS), used to confirm that the patient's tumor expresses the specific biomarker required for the therapy to be effective.

In highlighting key examples, there is little bit change in content from now. One of the most commercially successful Theranostics Market Products is the combination of $^ {177}\text{Lu-PSMA}$ (the therapeutic radioligand, like Pluvicto) and a corresponding diagnostic PSMA-PET tracer (like $^ {68}\text{Ga-PSMA}$ or $^ {18}\text{F-PSMA}$). These products target the Prostate-Specific Membrane Antigen (PSMA) expressed on prostate cancer cells. The high-performance PET/CT scanners and sophisticated Software & Services for personalized dosimetry are equally crucial market products that facilitate the safe and effective delivery of these powerful therapeutic agents. [Theranostics Market Products]